Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Duff & Phelps Investment Management Co.

Duff & Phelps Investment Management Co. reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,056 shares of the medical research company's stock after selling 3,041 shares during the quarter. Duff & Phelps Investment Management Co.'s holdings in Thermo Fisher Scientific were worth $11,994,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Stonegate Investment Group LLC boosted its stake in Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after purchasing an additional 18 shares during the period. Semus Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares during the last quarter. Bangor Savings Bank raised its stake in Thermo Fisher Scientific by 6.0% during the 4th quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock valued at $174,000 after acquiring an additional 19 shares during the last quarter. Eagle Rock Investment Company LLC increased its holdings in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after purchasing an additional 19 shares during the period. Finally, KRS Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.5% during the fourth quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock worth $685,000 after purchasing an additional 20 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Bank of America decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a report on Friday, January 10th. Finally, Citigroup dropped their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Thermo Fisher Scientific Trading Down 1.5 %

Shares of TMO traded down $7.37 during trading hours on Tuesday, hitting $490.23. The stock had a trading volume of 707,954 shares, compared to its average volume of 1,915,481. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 12-month low of $484.27 and a 12-month high of $627.88. The firm has a market cap of $184.94 billion, a P/E ratio of 29.66, a P/E/G ratio of 2.99 and a beta of 0.79. The company's fifty day simple moving average is $540.37 and its 200 day simple moving average is $551.02.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.41%.

Insider Buying and Selling

In related news, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company's stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock valued at $13,106,062 in the last quarter. Company insiders own 0.34% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.